AVITA Medical director buys 10,000 RCEL shares

AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of common stock in open-market transactions.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of common stock in open-market transactions. The purchases occurred at prices of $4.18 and $4.20 per share. A footnote indicates the reported holdings include unvested restricted stock units (RSUs).

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 2 txns

Insider Woody Joseph Fralin

Role Director

Bought 10,000 shs ($42K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$4.20	$21K
Purchase	Common Stock	5,000	$4.18	$21K

Holdings After Transaction: Common Stock — 102,761 shares (Direct)

Footnotes (1)

F1. Includes unvested RSUs

Key Figures

First purchase: 5,000 shares at $4.18 Second purchase: 5,000 shares at $4.20 Total net shares bought: 10,000 shares

3 metrics

First purchase 5,000 shares at $4.18 Open-market common stock buy coded P

Second purchase 5,000 shares at $4.20 Open-market common stock buy coded P

Total net shares bought 10,000 shares transactionSummary net-buy shares

Key Terms

open-market purchase, non-derivative, RSUs

3 terms

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

"transaction_type: "non-derivative""

RSUs financial

"Footnote: "Includes unvested RSUs""

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did AVITA Medical (RCEL) disclose for Woody Joseph Fralin?

AVITA Medical disclosed that director Woody Joseph Fralin bought 10,000 shares of common stock in open-market transactions. The purchases were reported on a Form 4 insider filing and involved two separate trades executed at different per-share prices.

How many AVITA Medical (RCEL) shares did Woody Joseph Fralin purchase and at what prices?

Woody Joseph Fralin purchased 10,000 AVITA Medical common shares in total. The Form 4 shows two open-market buys of 5,000 shares each, executed at per-share prices of $4.18 and $4.20, respectively, on the same reported transaction date.

Was the AVITA Medical (RCEL) insider transaction by Woody Joseph Fralin a buy or a sell?

The insider activity by Woody Joseph Fralin was a buy. The Form 4 reports two open-market purchase transactions, both coded as “P,” indicating purchases rather than sales, and transaction_summary data shows a net-buy of 10,000 shares.

Does Woody Joseph Fralin’s AVITA Medical (RCEL) filing involve derivatives or only common stock?

The filing involves only common stock transactions and no derivatives. Both reported entries are non-derivative common stock purchases, and the derivativeSummary section in the data is empty, indicating no option or warrant activity in this Form 4.

What does the footnote about unvested RSUs mean in the AVITA Medical (RCEL) Form 4?

The footnote states that the reported holdings include unvested RSUs, meaning some of Fralin’s position consists of restricted stock units that have not yet vested. These RSUs are part of his equity compensation and are counted within his disclosed ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/09/2026 - 04:58 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woody Joseph Fralin

(Last)

(First)

(Middle)

C/O AVITA MEDICAL 28159 AVENUE STANFORD

SUITE 220

(Street)

VALENCIA

CALIFORNIA

91355

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVITA Medical, Inc. [ RCEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/09/2026		P		5,000	A	$4.2	97,761⁽¹⁾	D
Common Stock	06/09/2026		P		5,000	A	$4.18	102,761⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Includes unvested RSUs

	/s/ Nicole Kelsey, by power of attorney	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR